Efficacy of re-resection versus radiofrequency ablation for recurrent Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma (HCC) after resection for primary HCC

被引:18
|
作者
Yin, Xieling [1 ]
Hua, Tianqi [2 ]
Liang, Chi [1 ]
Chen, Zhong [1 ]
机构
[1] Nantong Univ, Affiliated Hosp, Dept Hepatobiliary Surg, Nantong 226001, Peoples R China
[2] Changzhou Municipal Ctr Dis Control & Prevent, Inst TB & Chron Communicable Dis Control, Changzhou 213000, Peoples R China
基金
中国国家自然科学基金;
关键词
Recurrent hepatocellular carcinoma (recurrent HCC); radiofrequency ablation (RFA); repeat surgical resection (RSR); INTRAHEPATIC RECURRENCE; REPEAT HEPATECTOMY; HEPATIC RESECTION; SURGICAL RESECTION; OUTCOMES; CHEMOEMBOLIZATION; TRANSPLANTATION;
D O I
10.21037/tcr.2019.06.11
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Whether repeat surgical resection (RSR) or radiofrequency ablation (RFA) is a better option for recurrent hepatocellular carcinoma (HCC) after resection for primary HCC remains controversial. This study was to investigate the clinical efficacy of RSR versus RFA in the treatment of recurrent HCC at Barcelona Clinic Liver Cancer (BCLC) stage 0/A after resection of primary HCC. Methods: The patients treated by RSR (n=57) or RFA (n=51) for recurrent BCLC stage 0/A HCC in the Affiliated Hospital of Nantong University and Third Affiliated Hospital of Second Military Medical University from January 2008 to March 2018 were included. The general condition, clinicopathological characteristics, and survival were analyzed, and the baseline features and long-term survival were compared between two groups. Results: The baseline characteristics were comparable between two groups. The 1-, 3-, and 5-year survival rates were 96.5%, 80.9%, and 60.6% in RSR group, respectively, and 96.1%, 76.8%, and 59.4% in RFA group, respectively (P=0.48). The 1-, 3-, and 5-year overall survival (OS) rates after treatment for recurrent HCC were 78.9%, 50.5%, and 29.7% in RSR group, respectively, and 80.3%, 50.9%, and 26.0% in RFA group, respectively (P=0.67). The 1-, 3-, and 5-year disease-free survival rates were 68.4%, 39.4%, and 26.6% in RSR group, respectively, and 62.8%, 32.8%, and 20.4% in RFA group, respectively (P=0.55). The incidence of treatment-related complications was significantly higher in the RSR than in the RFA group (42.11% vs. 11.76%, P< 0.001). The median hospital stay was significantly shorter in the RFA than in the RSR group (3 vs. 9 days, P< 0.001). Conclusions: RSR and RFA have similar survival benefits in the treatment of recurrent BCLC stage 0/A HCC. RFA is superior to RSR in terms of hospital stay and incidence of treatment-related complications.
引用
收藏
页码:1035 / 1045
页数:11
相关论文
共 50 条
  • [1] Transarterial Chemoembolization versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma after Resection within Barcelona Clinic Liver Cancer Stage 0/A: A Retrospective Comparative Study
    Chen, Rongxin
    Gan, Yuhong
    Ge, Ninglin
    Chen, Yi
    Wang, Yan
    Zhang, Boheng
    Wang, Yanhong
    Ye, Shenglong
    Ren, Zhenggang
    [J]. JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2016, 27 (12) : 1829 - 1836
  • [2] Understanding the causes of recurrent HCC after liver resection and radiofrequency ablation
    Bosi, Carlo
    Rimini, Margherita
    Casadei-Gardini, Andrea
    Ercolani, Giorgio
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (05) : 503 - 515
  • [3] Radiofrequency ablation versus resection for Barcelona clinic liver cancer very early/early stage hepatocellular carcinoma: a systematic review
    He, Zhen-Xin
    Xiang, Pu
    Gong, Jian-Ping
    Cheng, Nan-Sheng
    Zhang, Wei
    [J]. THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2016, 12 : 295 - 303
  • [4] RADIOFREQUENCY ABLATION VERSUS SURGICAL RESECTION FOR THE TREATMENT OF EARLY STAGE HEPATOCELLULAR CARCINOMA (HCC) - A LARGE MULTICENTRE STUDY
    Gory, I.
    Fink, M.
    Bell, S.
    Gow, P.
    Nicoll, A.
    Knight, V.
    Dev, A.
    Rode, A.
    Kitson, M.
    Bailey, M.
    Kemp, W.
    Roberts, S. K.
    [J]. JOURNAL OF HEPATOLOGY, 2012, 56 : S392 - S393
  • [5] Survival Analysis of Re-resection Versus Radiofrequency Ablation for Intrahepatic Recurrence After Hepatectomy for Hepatocellular Carcinoma
    Chan, Albert C. Y.
    Poon, Ronnie T. P.
    Cheung, Tan To
    Chok, Kenneth S. H.
    Chan, See Ching
    Fan, Sheung Tat
    Lo, Chung Mau
    [J]. WORLD JOURNAL OF SURGERY, 2012, 36 (01) : 151 - 156
  • [6] Survival Analysis of Re-resection Versus Radiofrequency Ablation for Intrahepatic Recurrence After Hepatectomy for Hepatocellular Carcinoma
    Albert C. Y. Chan
    Ronnie T. P. Poon
    Tan To Cheung
    Kenneth S. H. Chok
    See Ching Chan
    Sheung Tat Fan
    Chung Mau Lo
    [J]. World Journal of Surgery, 2012, 36 : 151 - 156
  • [7] Liver resection for recurrent hepatocellular carcinoma after radiofrequency ablation therapy
    Yamagishi, Shunsuke
    Midorikawa, Yutaka
    Nakayama, Hisashi
    Higaki, Tokio
    Moriguchi, Masamichi
    Aramaki, Osamu
    Yamazaki, Shintaro
    Tsuji, Shingo
    Takayama, Tadatoshi
    [J]. HEPATOLOGY RESEARCH, 2019, 49 (04) : 432 - 440
  • [8] Liver resection is always a good choice for hepatocellular carcinoma (HCC) patients regardless of Barcelona Clinic Liver Cancer (BCLC) stage: the therapeutic hierarchy
    Guarino, Maria
    Caporaso, Nicola
    Morisco, Filomena
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (20)
  • [9] Recurrent HCC after Radiofrequency Ablation or Liver Resection Can Be Effectively Treated with Salvage Transplantation
    Muaddi, H.
    Al-Adra, D.
    Shaw, J.
    Grant, D.
    Greig, P.
    McGilvray, I.
    Cattral, M.
    Wei, A.
    Moulton, C. -A.
    Kachura, J.
    Beercroft, R.
    Selzner, M.
    Ghanekar, A.
    Gallinger, S.
    Cleary, S.
    Sapisochin, G.
    [J]. TRANSPLANTATION, 2017, 101 (05) : 60 - 60
  • [10] Recurrent HCC After Radiofrequency Ablation or Liver Resection Can Be Effectively Treated with Salvage Transplantation
    Muaddi, H.
    Al-Adra, D.
    Shaw, J.
    Grant, D.
    Greig, P.
    McGilvray, I.
    Cattral, M.
    Wei, A.
    Moulton, C. -A.
    Kachura, J.
    Beecroft, R.
    Selzner, M.
    Ghanekar, A.
    Gallinger, S.
    Cleary, S.
    Sapisochin, G.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 : 435 - 435